BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,123,629 | +42.8% | 80,532 | -6.8% | 0.07% | -23.7% |
| Q2 2023 | $1,486,906 | -4.8% | 86,448 | -8.2% | 0.10% | +54.0% |
| Q1 2023 | $1,561,803 | +128.8% | 94,198 | +5.1% | 0.06% | +57.5% |
| Q4 2022 | $682,737 | -18.8% | 89,598 | +5.9% | 0.04% | +8.1% |
| Q3 2022 | $841,000 | +9.5% | 84,598 | 0.0% | 0.04% | -35.1% |
| Q2 2022 | $768,000 | -17.9% | 84,598 | -8.2% | 0.06% | 0.0% |
| Q1 2022 | $936,000 | -58.3% | 92,198 | -31.5% | 0.06% | -51.3% |
| Q4 2021 | $2,243,000 | -77.8% | 134,498 | -75.5% | 0.12% | -85.3% |
| Q3 2021 | $10,093,000 | -21.9% | 548,184 | -5.7% | 0.80% | -47.6% |
| Q2 2021 | $12,919,000 | +6.8% | 581,178 | +12.7% | 1.52% | -72.9% |
| Q1 2021 | $12,098,000 | – | 515,769 | – | 5.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |